Rubicon Research Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's consolidated revenue from operations for the quarter stood at ₹4,755.29 million (₹475.53 crore), a significant increase from ₹3,133.96 million (₹313.40 crore) in the same period last year. The net profit after tax for the quarter was ₹727.97 million (₹72.80 crore), compared to ₹380.73 million (₹38.07 crore) in the corresponding quarter of the previous year. For the nine-month period ended December 31, 2025, consolidated revenue from operations was ₹12,400.41 million (₹1,240.04 crore), up from ₹9,261.25 million (₹926.13 crore) in the prior year. The net profit after tax for the nine months surged to ₹1,699.50 million (₹169.95 crore) from ₹981.16 million (₹98.12 crore) in the same period last year. The company also reported its standalone financial results. For the quarter ended December 31, 2025, standalone revenue from operations was ₹3,017.11 million (₹301.71 crore), and the net profit after tax was ₹371.81 million (₹37.18 crore). For the nine-month period, standalone revenue was ₹9,162.04 million (₹916.20 crore), with a net profit after tax of ₹1,181.45 million (₹118.15 crore). Key events during the period included the completion of an Initial Public Offering (IPO) aggregating to ₹13,775.00 million (₹1,377.50 crore) on November 21, 2025. The company's equity shares were listed on NSE and BSE on October 16, 2025. Furthermore, the group entered into definitive agreements to invest USD 3.00 million in Gen1e Lifesciences Inc. and USD 2.5 million in Neuronasal Inc., with USD 2.00 million already invested in Gen1e Lifesciences Inc. Subsequent to the quarter, on January 30, 2026, the Goods and Services Tax (GST) Department initiated an inspection/search at the company's premises. The company is cooperating with the authorities and believes it has complied with applicable GST laws.
